Nilanjan Ghosh

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, doub...

Ublituximab plus ibrutinib versus ibrutinib bij hoogrisico recidief CLL: GENUINE fase III